Quoin Pharmaceuticals Ltd experiences significant decline amid market conditions.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 05 Dec 25
Source: Coinmarketcap
Quoin Pharmaceuticals Ltd's stock fell by 23.32%, crossing down the 20-day SMA, reflecting a challenging trading environment.
The broader market showed mixed signals, with the Nasdaq-100 up 0.51% and the S&P 500 up 0.30%, indicating sector-specific issues affecting Quoin Pharmaceuticals.
This decline raises concerns about the company's performance and may lead to increased scrutiny from investors in the upcoming trading sessions.
Analyst Views on QNRX
Wall Street analysts forecast QNRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNRX is 70.00 USD with a low forecast of 70.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.100
Low
70.00
Averages
70.00
High
70.00
Current: 9.100
Low
70.00
Averages
70.00
High
70.00
No data
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
